Skip to main content

Table 1 Summary of Trial Characteristics

From: Intra-articular platelet-rich plasma injections versus intra-articular corticosteroid injections for symptomatic management of knee osteoarthritis: systematic review and meta-analysis

Study Sample (n) Dropouts Study Design Population Intervention design Follow-up period Outcome Measurement
Huang et al. (2019) [26] 265 recruited
120 participants
(46% female)
40 received PRP, 40 received CS and 40 HA (HA patients not included)
0
145 did not meet inclusion criteria
Prospective, randomised study Kellgren/Lawrence grade 1–2
Aged 40–65
Chinese patients recruited from May 2016
1 injection per group, received once
Anatomically guided injections
4 ml LP-PRP
1 ml corticosteroid
12 months WOMAC and VAS scores at 3, 6,9- and 12-months post intervention
Khan et al. (2018) [29] 150 patients recruited
101 participants
(76.5% female)
52 received PRP, 51 received CS
49 Randomised control trial Kellgren/Lawrence grade 2 and ACR osteoarthritis criteria
Aged 40–63
Pakistani patients recruited between July ‘17-July ‘18
2 injections per group, given at 0 months and 2 months.
Anatomically guided injections
5 ml PRP (LR/LP not specified)
1 mil (40 mg) triamcinolone
6 months WOMAC and VAS scores at 2 months, then every 2 weeks until 6 months
Naderi et al. (2018) [30] 72 recruited
67 participated
(82% female)
33 received PRP,
34 received corticosteroids
5 Randomised control trial with Quad
ruple block randomisation
Kellgren/Lawrence or ACR grade 2–3 osteoarthritis
Aged 30–75
Iranian patients between April ‘16- June ‘17, recruited in a hospital
3 injections performed once a month for 3 consecutive months in both groups
Ultrasound guided injections
5 ml LR-PRP
40 mg triamcinolone
6 months VAS and KOOS scores before the onset of treatment, once a month after treatment and 6 months after treatment.
Freire et al. (2018) [28] 50 patients (25 PRP, 25 corticosteroids)
(84% female)
Double-blinded block randomisation
0 Randomised, controlled, longitudinal, double blind, comparative, descriptive study Kellgren/Lawrence 2–4
Aged 30–90
Brazilian patients, recruited in a medical centre
1 injection performed once in each group
Anatomically guided injections
5 ml LP- PRP
2.5 ml triamcinolone
6 months KSS, WOMAC, Kellgren-Lawrence scores evaluated before treatment, at 1 months and 6 months post-intervention
Camurcu et al. (2018) [31] 132 patients recruited
(83% female)
37 PRP, 40 PRP+ steroid, 38 steroid
17 Prospective longitudinal study Kellgren-Lawrence grade 2–3
Aged 40–80
Turkish patients recruited in 2016
1 injection of PRP only, PRP + steroid, or steroid only
Anatomically guided injection
3 ml LR-PRP
1 ml methylprednisolone
12 months (for 115 patients) VAS and WOMAC at 1,3, 6- and 12-months post-intervention
Phul et al. (2018) [27] 80 patients recruited
40 in each group: PRP or corticosteroid
(67.5% female)
0 Randomised control trial Kellgren/Lawrence grade 2–4
Aged 40–75
Pakistani patients recruited between Feb- August 2015
1 injection in both groups
Anatomically guided injection for PRP; fluoroscopically guided corticosteroid injection
4–6 microml LR-PRP
40 ml triamcinolone
3 months VAS at baseline and 3 months post-intervention
Uslu et al. (2017) [20] 57 patients recruited
50 participants (92% female)
17 received CS, 19 single PRP, 14 triple PRP injection
7 Prospective, randomised, single-blind (physician blind) Kellgren/Lawrence grade 3
Aged 50–75
Turkish patients between June ‘15- March ‘16, hospital setting
3 groups receiving either 1 PRP injection, 3 PRP injections (given 1 week apart) or 1 steroid injection
Anatomically guided injections
LR-PRP, dose not specified
Corticosteroid suspension equivalent to 5 mg betamethasone
6 months VAS, WOMAC and HAD scale (an assessment of anxiety and depression) with follow up at baseline, 2 and 6 months post-intervention
Jubert et al. (2017) [22] 65 patients included
(72% female)
35 PRP, 30 corticosteroid
0 Prospective randomised, double-blind, parallel controlled study Kellgren/Lawrence grade 3–4
Aged 40–80
Patients between Aug ‘13- July ‘14
1 injection per group given once
Anatomically guided injections
4 ml LP-PRP
2 ml betamethasone
6 months VAS, KOOS and SF36 scores at 1, 3- and 6-months post-intervention